Back to News
Market Impact: 0.4
Moderna Turns a Profit as R&D Spending Falls: Rapid Earnings Reaction
Source: fool.com
Healthcare & BiotechCorporate EarningsCorporate Guidance & OutlookCompany Fundamentals
Moderna revenue jumped 29%, driven by international COVID vaccine sales tied to long-term government deals. The company raised its 2026 revenue growth outlook to 15%–25%.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
MRNA0.75
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Stocks making the biggest moves midday: Nvidia, Moderna, IonQ, Airbnb, Firefly Aerospace & more
- While biotech bets swing on trial data, this dividend payer gained 72% since 2024
- 5 Things Investors Need to Know About Friday's Markets
- Our top 10 things to watch in the stock market Friday
- Stocks making the biggest moves premarket: Moderna, Airbnb, Cloudflare, Affirm & more